Generalized anxiety disorder: An important clinical concern

Medical Clinics of North America

Volumn 85, Issue 3, 2001, Pages 691-710

  Hidalgo, Rosario B ^b   Davidson, Jonathan R T ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2' CHLORNORDIAZEPAM; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CLORAZEPATE; DIAZEPAM; HYDROXYZINE; IMIPRAMINE; NORDAZEPAM; PAROXETINE; PLACEBO; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; GABAERGIC SYSTEM; HEALTH CARE COST; HUMAN; NEUROBIOLOGY; NEUROCHEMISTRY; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035035992     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70336-9     Document Type: Article

References (79)

1. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder
2. The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder
3. Comorbidity and depression among the anxiety disorders: Issues in diagnosis and classification
4. Generalized anxiety and generalized anxiety disorder: Description and reconceptualization
5. Stressful life events and the onset of generalized anxiety syndrome
6. Generalized anxiety disorder
7. Psychosocial treatment for GAD
8. Psychiatric comorbidity in patients with generalized anxiety disorder
9. Biological findings in GAD: CCKB agonist challenge
10. Generalized anxiety disorder: Issues in epidemiology
11. Biological basis of generalized anxiety disorder
12. CSF serotonin: Diagnostic and seasonal differences
13. Comorbidity among anxiety disorders: Implications for treatment and DSM-IV
14. Adrenergic status in anxiety disorders: Platelet alpha two-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and normal subjects
15. Generalized anxiety disorder after stroke
16. Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorder
17. Double-blind comparison of buspirone and clorazepate in anxious outpatients
18. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives
19. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
20. Pharmacotherapy of generalized anxiety disorder
21. Slow wave sleep and 5-HT2 receptor sensitivity in GAD: A pilot study with ritanserin
22. Comorbidity among the anxiety disorders
23. Course and psychosocial impairment in GAD
24. Epidemiology of anxiety disorders in Florence
25. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: Reversal after chronic diazepam treatment
26. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety disorder
27. The justification for detecting from neurasthenia a particular syndrome: The anxiety neurosis
28. Examination of comorbid anxiety in psychiatric inpatients
29. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid
30. Anger and anxiety response to m-chlorophenylpiperazine in generalized anxiety disorder
31. The economic burden of anxiety disorders in the 1990s
32. Drug therapy: Current status of benzodiazepines
33. Mental disorders and migraine: Epidemiologic studies
34. Somatic manifestations in women with generalized anxiety disorder
35. Studies of a neurochemical link between depression, anxiety, and stress from [3H] imipramine and [3H] paroxetine binding on human platelets
36. Neurotic illness and its response to anxiolytic and antidepressant treatment
37. Comorbidity as fundamental feature of generalized anxiety disorder: Results from the NCS
38. Distressed high utilizers of medical care: DSM-III diagnoses among distressed and treatment needs
39. Past-year use of outpatient service for psychiatric problems in the national comorbidity survey
40. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national studies
41. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder
42. Anxiety and cerebral blood flow
43. Generalized anxiety disorder vs. panic disorder: Distinguishing characteristics and patterns of comorbidity
44. Neurobiological mechanisms in generalized anxiety disorder
45. Panic and generalized anxiety disorder: Developmental antecedents and precipitants
46. Buspirone and diazepam in anxiety: A controlled study
47. Long term diazepam therapy and clinical outcome
48. Clorazepate and lorazepam: Clinical improvement and rebound anxiety
49. Long term treatment of anxiety and risk of withdrawal: Prospective comparison of clorazepate and buspirone
50. Buspirone in major depression: A controlled study
51. Antidepressants for the treatment of GAD: A placebo-controlled comparison of imipramine, trazodone, and diazepam
52. Paroxetine efficacy in the treatment of GAD
53. Prevalence of medical illness in patients with anxiety disorders
54. Urinary free cortisol levels in anxiety
55. Emergence of hostility during alprazolam treatment
56. Generalized anxiety disorder in primary care: The precursor/ modifier pathway to increased health care utilization
57. Chronic anxiety and generalized anxiety disorder: Issues in comorbidity
58. Platelet [3H] imipramine binding in GAD, panic disorder, and agoraphobia with panic attacks
59. Buspirone in the treatment of panic disorder: A controlled pilot comparison with clorazepate
60. Maintenance drug treatment for panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine
61. Pharmacological treatment for GAD
62. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects
63. Is buspirone effective for panic disorder?
64. Treatment of anxiety with buspirone
65. Autonomic characteristics of generalized anxiety disorder and worry
66. Ages of onset of DSM-III anxiety disorders
67. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: A fractal analysis
68. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder
69. Identification of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R using the Composite International Diagnostic Interview (CIDI)
70. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients
71. DSM-III-R generalized anxiety disorder in the national comorbidity survey
72. Nature and course of GAD
73. PET in generalized anxiety disorder
74. Phenomenology and course of generalized anxiety disorder